Headlines:
Tag: FDA
MolecuLight Receives FDA 510(k) Clearance for its i:X® Handheld Fluorescence Imaging Device for Wound Management

MolecuLight Receives FDA 510(k) Clearance for its i:X® Handheld Fluorescence Imaging Device for Wound Management

December 5, 2019 Economie

New FDA Approval Extends Label to Including the i:X's Detection of Bacteria and Digital Wound Measurement TORONTO, Dec. 5, 2019 /CNW/ - MolecuLight Inc., the world's leader in ...

Lees verder
Hovione Announces Successful End-of-phase 2 Meeting With the FDA and Outlines Phase 3 Program for Minocycline Topical Gel

Hovione Announces Successful End-of-phase 2 Meeting With the FDA and Outlines Phase 3 Program for Minocycline Topical Gel

September 22, 2019 Economie

CORK, Ireland, Sept. 20, 2019 /PRNewswire/ -- Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the ...

Lees verder
Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skippin

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skippin

September 11, 2019 Economie

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications ...

Lees verder
Super Antioxidant Ergothioneine Achieves GRAS Status from FDA

Super Antioxidant Ergothioneine Achieves GRAS Status from FDA

August 21, 2019 Economie

Decision Drives Anti-Aging Market Emerging Studies Reveal Ergothioneine consumption is Correlated to Reducing Mild Cognitive Impairment RANCHO SANTA MARGARITA, California, ...

Lees verder
FDA Premarket Approval Granted for DT MedTech's Hintermann Series H3(TM) Total Ankle Replacement System

FDA Premarket Approval Granted for DT MedTech's Hintermann Series H3(TM) Total Ankle Replacement System

June 5, 2019 Economie

BALTIMORE, June 5, 2019 /PRNewswire/ -- DT MedTech, LLC (DTM) announced today that the Hintermann Series H3(TM) (H3) Total Ankle Replacement (TAR) System has received ...

Lees verder
Office of Generic Drugs (OGD/FDA) Awards $1M FDA Contract to CUBRC and EpiVax for Demonstration and Validation of Immunogenicity Risk Assessment

Office of Generic Drugs (OGD/FDA) Awards $1M FDA Contract to CUBRC and EpiVax for Demonstration and Validation of Immunogenicity Risk Assessment

October 2, 2018 Economie

PROVIDENCE, Rhode Island, Oct. 2, 2018 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announced today that they have been awarded a two-year $1 million ...

Lees verder
Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

August 8, 2018 Economie

TOKYO, August 8, 2018 /PRNewswire/ -- - Poteligeo has been approved for the treatment of the two most common types of Cutaneous T-cell lymphoma (CTCL) in ...

Lees verder
Norgine Announces US FDA Approval for PLENVU® (NER1006) – 1 Litre PEG Based Bowel Cleansing Preparation for Colonoscopy

Norgine Announces US FDA Approval for PLENVU® (NER1006) – 1 Litre PEG Based Bowel Cleansing Preparation for Colonoscopy

May 7, 2018 Economie

AMSTERDAM, May 7, 2018 /PRNewswire/ -- - US launch date: second half of 2018  - In Europe, PLENVU(R) is available through Norgine  Norgine B.V. today ...

Lees verder
Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboemboli

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboemboli

April 30, 2018 Economie

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension ...

Lees verder
Kazia Receives FDA Orphan Designation for GDC-0084

Kazia Receives FDA Orphan Designation for GDC-0084

February 24, 2018 Economie

SYDNEY, Feb. 23, 2018 /PRNewswire/ -- Kazia Therapeutics Limited , an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and ...

Lees verder
Nieuwe berichten
BizPress.nl